88 related articles for article (PubMed ID: 19270491)
1. Stage-specific effect of inhibition of autophagy on chemotherapy-induced cytotoxicity.
Shingu T; Fujiwara K; Bögler O; Akiyama Y; Moritake K; Shinojima N; Tamada Y; Yokoyama T; Kondo S
Autophagy; 2009 May; 5(4):537-9. PubMed ID: 19270491
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of autophagy at a late stage enhances imatinib-induced cytotoxicity in human malignant glioma cells.
Shingu T; Fujiwara K; Bögler O; Akiyama Y; Moritake K; Shinojima N; Tamada Y; Yokoyama T; Kondo S
Int J Cancer; 2009 Mar; 124(5):1060-71. PubMed ID: 19048625
[TBL] [Abstract][Full Text] [Related]
3. Appropriate modulation of autophagy sensitizes malignant peripheral nerve sheath tumor cells to treatment with imatinib mesylate.
Okano M; Sakata N; Ueda S; Takemura T
J Pediatr Hematol Oncol; 2014 Apr; 36(3):200-11. PubMed ID: 24136016
[TBL] [Abstract][Full Text] [Related]
4. Carvedilol in glioma treatment alone and with imatinib in vitro.
Erguven M; Yazihan N; Aktas E; Sabanci A; Li CJ; Oktem G; Bilir A
Int J Oncol; 2010 Apr; 36(4):857-66. PubMed ID: 20198329
[TBL] [Abstract][Full Text] [Related]
5. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells.
Lu Y; Liu LL; Liu SS; Fang ZG; Zou Y; Deng XB; Long ZJ; Liu Q; Lin DJ
J Transl Med; 2016 Sep; 14():270. PubMed ID: 27645552
[TBL] [Abstract][Full Text] [Related]
7. Imatinib induces autophagy through BECLIN-1 and ATG5 genes in chronic myeloid leukemia cells.
Can G; Ekiz HA; Baran Y
Hematology; 2011 Mar; 16(2):95-9. PubMed ID: 21418740
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of PDGFR by imatinib elicits the sustained activation of ERK and downstream receptor signaling in malignant glioma cells.
Dong Y; Jia L; Wang X; Tan X; Xu J; Deng Z; Jiang T; Rainov NG; Li B; Ren H
Int J Oncol; 2011 Feb; 38(2):555-69. PubMed ID: 21152856
[TBL] [Abstract][Full Text] [Related]
9. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological agents with inherent anti-autophagic activity improve the cytotoxicity of imatinib.
Crowley LC; O'Donovan TR; Nyhan MJ; McKenna SL
Oncol Rep; 2013 Jun; 29(6):2261-8. PubMed ID: 23564048
[TBL] [Abstract][Full Text] [Related]
11. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
Kuroda J; Puthalakath H; Cragg MS; Kelly PN; Bouillet P; Huang DC; Kimura S; Ottmann OG; Druker BJ; Villunger A; Roberts AW; Strasser A
Proc Natl Acad Sci U S A; 2006 Oct; 103(40):14907-12. PubMed ID: 16997913
[TBL] [Abstract][Full Text] [Related]
12. Modulation of imatinib cytotoxicity by selenite in HCT116 colorectal cancer cells.
Abdel-Aziz AK; Azab SS; Youssef SS; El-Sayed AM; El-Demerdash E; Shouman S
Basic Clin Pharmacol Toxicol; 2015 Jan; 116(1):37-46. PubMed ID: 24930392
[TBL] [Abstract][Full Text] [Related]
13. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
15. The anticancer drug imatinib induces cellular autophagy.
Ertmer A; Huber V; Gilch S; Yoshimori T; Erfle V; Duyster J; Elsässer HP; Schätzl HM
Leukemia; 2007 May; 21(5):936-42. PubMed ID: 17330103
[TBL] [Abstract][Full Text] [Related]
16. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
18. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of dual-specific Bcr-Abl and Src-family kinase inhibitors in cells sensitive and resistant to imatinib mesylate.
Tipping AJ; Baluch S; Barnes DJ; Veach DR; Clarkson BM; Bornmann WG; Mahon FX; Goldman JM; Melo JV
Leukemia; 2004 Aug; 18(8):1352-6. PubMed ID: 15201856
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effect of imatinib in gastrointestinal stromal tumors: AKT signaling dependent and independent mechanisms.
Tarn C; Skorobogatko YV; Taguchi T; Eisenberg B; von Mehren M; Godwin AK
Cancer Res; 2006 May; 66(10):5477-86. PubMed ID: 16707477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
